Digging into Deals: What's Behind Pfizer's Record-Breaking Acquisition of Allergan

TL;DR

Pfizer's $160B acquisition of Allergan driven by strategic importance and potential tax savings.

Transcript

Kristine Harjes: Todd, do you want to pick an M&A story from 2015, and we'll walk through it? Todd Campbell: Yeah. There were a ton. Michael Douglass: We're in kind of a target-rich environment. Campbell: Very much so! Record year for M&A deals in the healthcare space this past year. You had touched on this, these aren't mutually exclusive. When yo... Read More

Key Insights

• 💋 Pfizer's acquisition of Allergan was a mega healthcare M&A deal, marking a record year for such transactions in 2015.
• 🤝 The deal was motivated by a combination of potential tax savings and strategic importance in driving revenue growth globally.
• 😓 Market suspicions and regulatory concerns cast uncertainty on the deal's successful completion.

Questions & Answers

Q: What were the key drivers behind Pfizer's acquisition of Allergan?

Pfizer's acquisition of Allergan was primarily driven by the potential tax savings associated with moving its headquarters overseas to a country with a lower corporate tax rate.

Q: How did the market view the multiple of Pfizer's stock offered for Allergan's shares in the deal?

Despite the calculated multiple, there were suspicions in the market regarding the deal's likelihood of success, with concerns about regulatory pushback and uncertainties impacting both companies' stock prices.

Q: What strategic importance did Pfizer and Allergan emphasize in the acquisition?

Both companies highlighted the strategic importance of combining their franchises to drive revenue growth and expand into new markets, beyond just the tax benefits associated with the deal.

Q: What risk considerations were associated with Pfizer's acquisition of Allergan?

As both companies were commercial-stage entities, the risk of the deal imploding was considered low, given the mature nature of their operations and established cashflow generation capabilities.

Summary & Key Takeaways

• Pfizer's proposed acquisition of Allergan in 2015 valued at $160B would create the largest pharma company on the planet.

• The deal was driven by potential tax savings as Pfizer, a U.S.-based company, sought to lower its corporate tax rate.

• Both companies highlighted the strategic importance of combining their franchises for revenue growth and market expansion.